Affordable Access

Current status of high dose chemotherapy in breast cancer.

Authors
Type
Published Article
Journal
Przegla̧d lekarski
Publication Date
Volume
57 Suppl 1
Pages
30–32
Identifiers
PMID: 10822993
Source
Medline
License
Unknown

Abstract

To date, no definite answers are available to the initial question, whether or not HDCT and ASCT can improve quantity or quality of life. Completing the available prospective, randomized phase III studies; using HDCT earlier in the course of treatment; applying drugs that are active breast cancer; comparing the experimental treatment to standard therapy; and using appropriate sample size to detect clinically meaningful and statistically significant differences are all paramount requirements to answer the question successfully. Within the next few years, a number of European [13] and two Canadian Studies [6, 14] that are currently accruing patients, will contribute versus important information regarding the role of HDCT and ABMT for breast cancer.

Statistics

Seen <100 times